Patents by Inventor Oliver Lenz

Oliver Lenz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof
    Publication number: 20160159803
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 9, 2016
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof
    Publication number: 20160158238
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 9, 2016
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominque Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • Pteridines useful as HCV inhibitors and methods for the preparation thereof
    Patent number: 9290502
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: March 22, 2016
    Assignee: JANSSEN SCIENCES IRELAND UC
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • COFACTOR REGENERATION SYSTEM
    Publication number: 20150044723
    Abstract: The present invention relates to cofactor regeneration systems, components and uses thereof and methods for generating and regenerating cofactors. The cofactor regeneration system comprises a first electron transfer component selected from a polypeptide comprising a NADH:acceptor oxido-reductase or NADPH:acceptor oxido-reductase, a second electron transfer component selected from a hydrogenase moiety and/or non-biological nanoparticles and an electronically conducting surface. The first and second electron transfer components are immobilised on the electrically conducting surface, and the first and second electron transfer components do not occur together in nature as an enzyme complex.
    Type: Application
    Filed: October 3, 2012
    Publication date: February 12, 2015
    Inventors: Kylie Vincent, Lars Lauterbach, Oliver Lenz
  • Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof
    Publication number: 20140094468
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Application
    Filed: December 3, 2013
    Publication date: April 3, 2014
    Applicant: Tibotec Pharmaceuticals Ltd.
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominique LouisNestorGhislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside
    Publication number: 20130028865
    Abstract: The present invention relates to a combination of a macrocyclic HCV protease inhibitor, a macrocyclic non-nucleoside HCV polymerase inhibitor and a nucleoside HCV polymerase inhibitor.
    Type: Application
    Filed: April 13, 2011
    Publication date: January 31, 2013
    Applicants: MEDIVIR AB, JANSSEN PHARMACEUTICALS, INC.
    Inventors: Tse-I Lin, Oliver Lenz, Pierre Jean-Marie Bernard Raboisson
  • Fused bicyclic inhibitors of HCV
    Patent number: 8030318
    Abstract: Substituted fused bicyclic pyrimidine compounds having an amide-substituted pyridylamine group at C-4 of the pyrimidine ring are useful in the treatment of conditions associated with HCV.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: October 4, 2011
    Assignee: Tibotec Pharmaceuticals Ltd.
    Inventors: Kenneth Alan Simmen, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Pierre Jean-Marie Bernard Raboisson, Sarvajit Chakravarty, Barry Patrick Hart
  • Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
    Patent number: 8022077
    Abstract: The present invention relates to the use of pyrido[2,3-d]pyrimidines of formula (I) wherein L, R1, R2 and R3 have specific meaning. The present invention also relates to the use of the compounds of formula (I) as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds of formula (I) per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: September 20, 2011
    Assignee: Tibotec Pharmaceuticals Ltd.
    Inventors: Kenneth Alan Simmen, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Pierre Jean-Marie Bernard Raboisson
  • Synergistic Combinations of a Macrocyclic Inhibitor of HCV and a Nucleoside
    Publication number: 20110171174
    Abstract: The present invention relates to a synergistic combination of the compound of formula I: or a pharmaceutically acceptable salt thereof, and the compound of formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 18, 2009
    Publication date: July 14, 2011
    Applicant: ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.
    Inventors: Tse-I Lin, Oliver Lenz
  • HCV inhibiting bi-cyclic pyrimidines
    Patent number: 7977342
    Abstract: The present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present bi-cyclic pyrimidines with other anti-HCV agents.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: July 12, 2011
    Assignee: Tibotec-Virco Virology BVBA
    Inventors: Kenneth Alan Simmen, Tse-I Lin, Oliver Lenz, Dominique Louis Nestor Ghislain Surleraux, Pierre Jean-Marie Bernard Raboisson
  • CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS
    Publication number: 20090247523
    Abstract: The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]-pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.
    Type: Application
    Filed: October 4, 2007
    Publication date: October 1, 2009
    Inventors: Pierre Jean-Marie Bernard Raboisson, Oliver Lenz, Tse-I Lin, Kenneth Simmen
  • Pteridines useful as HCV inhibitors and methods for the preparation thereof
    Publication number: 20090156595
    Abstract: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Application
    Filed: May 12, 2006
    Publication date: June 18, 2009
    Applicant: Tibotec Pharmaceuticals Ltd.
    Inventors: Pierre Jean-Marie Bernard Raboisson, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Kenneth Alan Simmen
  • PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF
    Publication number: 20090131460
    Abstract: The present invention relates to the use of pyrido[2,3-d]pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to pyrido-[2,3-d]pyrimidines compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
    Type: Application
    Filed: May 12, 2006
    Publication date: May 21, 2009
    Applicant: TIBOTEC PHARMACEUTICALS LTD.
    Inventors: Kenneth Alan Simmen, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Pierre Jean-Marie Bernard Raboisson
  • Inhibitors of Infection
    Publication number: 20090011000
    Abstract: Fusion inhibitor peptides are provided comprising a sequence derived from an HR2 domain. In preferred embodiments, the peptides are capable of oligomerization. Also provided are nucleic acids encoding the peptides, vectors comprising the nucleic acids and host cells transformed with the vectors. The peptides may be used as medicaments. Also provided are methods for expressing a protein comprising one or more transmembrane domain(s) in an expression system. The methods comprise fusing a sequence encoding an 18-mer peptide, or a functional equivalent thereof, to a gene encoding the protein and expressing the resultant gene-fusion product in an expression system.
    Type: Application
    Filed: October 7, 2005
    Publication date: January 8, 2009
    Inventors: Andreas Hinz, Oliver Lenz, Winfried Weissenhorn
  • Fused Bicyclic Inhibitors of Hcv
    Publication number: 20080182863
    Abstract: Certain appropriately substituted fused bicyclic pyrimidine compounds having an amide-substituted pyridylamine group at C-4 of the pyrimidine ring are useful in the treatment of conditions associated with HCV.
    Type: Application
    Filed: March 27, 2006
    Publication date: July 31, 2008
    Inventors: Kenneth Alan Simmen, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Pierre Jean-Marie Bernard Raboisson, Sarvajit Chakravarty, Barry Patrick Hart
  • Biochemical Fuel Cell
    Publication number: 20070248845
    Abstract: A fuel cell and a method of operating the fuel cell, which fuel cell comprises an anode having a catalyst adsorbed thereon, said catalyst comprising an oxygen tolerant hydrogenase enzyme, in particular a hydrogenase from Ralstonia eutropha. The hydrogenase enzyme is typically also tolerant to carbon monoxide.
    Type: Application
    Filed: September 13, 2005
    Publication date: October 25, 2007
    Inventors: Fraser Armstrong, Kylie Vincent, Baerbel Friedrich, Oliver Lenz
  • HCV INHIBITING BI-CYCLIC PYRIMIDINES
    Publication number: 20070155716
    Abstract: The present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present bi-cyclic pyrimidines with other anti-HCV agents.
    Type: Application
    Filed: March 9, 2007
    Publication date: July 5, 2007
    Inventors: Kenneth SIMMEN, Tse-I Lin, Oliver Lenz, Dominique Louis Surleraux, Pierre Jean-Marie Raboisson
  • Web twister removal process
    Patent number: 7065948
    Abstract: An apparatus for detecting and eliminating a twister in a running web of flexible material. The apparatus includes a catch section for twisters, a rotor, a scanner arrangement for detection of a twister that has entered a catch section and a control unit , which, upon detection of a twister by the scanner, triggers the drive of the rotor for untwisting the twister.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: June 27, 2006
    Assignee: The Procter & Gamble Company
    Inventors: Martin Kranich, Oliver Lenz
  • Web twister removal process
    Publication number: 20040129752
    Abstract: An apparatus for detecting and eliminating a twister in a running web of flexible material comprises
    Type: Application
    Filed: December 18, 2003
    Publication date: July 8, 2004
    Applicant: The Procter & Gamble Company
    Inventors: Martin Kranich, Oliver Lenz